Aripiprazole as adjunctive therapy for patients with major depressive disorder: Overview and implications of clinical trial data

CNS Drugs

Volumn 25, Issue 2, 2011, Pages 109-127

  Pae, Chi Un ^a,b   Forbes, Andy ^c   Patkar, Ashwin A ^b  

^a The Catholic University of Korea   (South Korea)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

Antipsychotics, general; Aripiprazole, general; Depression

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CITALOPRAM; DESIPRAMINE; ESCITALOPRAM; FLUOXETINE; LAMOTRIGINE; MINALCIPRAN; PAROXETINE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SERTRALINE; UNCLASSIFIED DRUG; VENLAFAXINE;

ABSCESS; ADD ON THERAPY; AKATHISIA; ARTERY OCCLUSION; BLURRED VISION; CELLULITIS; CONSTIPATION; CONTUSION; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXOSTOSIS; FATIGUE; HEADACHE; HUMAN; INSOMNIA; MAJOR DEPRESSION; NAUSEA; NONHUMAN; PHARMACODYNAMICS; PNEUMONIA; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RESTLESSNESS; REVIEW; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; TARDIVE DYSKINESIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREMOR; URINARY TRACT INFECTION; WEIGHT GAIN; XEROSTOMIA;

ANIMALS; CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER, MAJOR; DRUG INTERACTIONS; HUMANS; PIPERAZINES; QUINOLONES;

EID: 78951471427     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11538980-000000000-00000     Document Type: Review

References (103)

1. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003 Jun 18; 289 (23): 3095-105
2. Fava M, Rush AJ, Trivedi MH, et al. Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. Psychiatr Clin North Am 2003 Jun; 26 (2): 457-94, x
3. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006 Jan; 163 (1): 28-40
4. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006 Nov; 163 (11): 1905-17
5. Papakostas GI, Petersen T, Denninger JW, et al. Psychosocial functioning during the treatment of major depressive disorder with fluoxetine. J Clin Psychopharmacol 2004 Oct; 24 (5): 507-11
6. Trivedi MH, Corey-Lisle PK, Guo Z, et al. Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning. Int Clin Psychopharmacol 2009 May; 24 (3): 133-8
7. Moller HJ. Outcomes in major depressive disorder: the evolving concept of remission and its implications for treatment. World J Biol Psychiatry 2008; 9 (2): 102-14
8. Nierenberg AA, Husain MM, Trivedi MH, et al. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med 2009 May; 22: 1-10
9. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000 Apr; 157 (4 Suppl.): 1-45
10. Bauer M, Whybrow PC, Angst J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders: part 1. Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 2002 Jan; 3 (1): 5-43
11. Anderson IM, Ferrier IN, Baldwin RC, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 2008 Jun; 22 (4): 343-96
12. Kennedy SH, Lam RW, Cohen NL, et al. Clinical guide-lines for the treatment of depressive disorders: IV. Medications and other biological treatments. Can J Psychiatry 2001 Jun; 46 Suppl. 1: 38S-58S
13. Appelberg BG, Syvalahti EK, Koskinen TE, et al. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebocontrolled, randomized, double-blind, placebo wash-in study. J Clin Psychiatry 2001 Jun; 62 (6): 448-52
14. Blier P, Ward NM. Is there a role for 5-HT1A agonists in the treatment of depression? Biol Psychiatry 2003; 53 (3): 193-203
15. Corrigan MH, Denahan AQ, Wright CE, et al. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 2000; 11 (2): 58-65
16. Cassano P, Lattanzi L, Fava M, et al. Ropinirole in treat-ment-resistant depression: a 16-week pilot study. Can J Psychiatry 2005 May; 50 (6): 357-60
17. Rasmussen NA, Schroder P, Olsen LR, et al. Modafinil augmentation in depressed patients with partial response to antidepressants: a pilot study on self-reported symptoms covered by the Major Depression Inventory (MDI) and the Symptom Checklist (SCL-92). Nord J Psychiatry 2005; 59 (3): 173-8
18. DeBattista C, Doghramji K, Menza MA, et al. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebocontrolled study. J Clin Psychiatry 2003 Sep; 64 (9): 1057-64
19. Konuk N, Atasoy N, Atik L, et al. Open-label study of ad-junct modafinil for the treatment of patients with fatigue, sleepiness, and major depression treated with selective serotonin reuptake inhibitors. Adv Ther 2006 Jul-Aug; 23 (4): 646-54
20. Thase ME, Fava M, DeBattista C, et al. Modafinil aug-mentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study. CNS Spectr 2006 Feb; 11 (2): 93-102
21. Dunlop BW, Critschristoph P, Evans DL, et al. Coad-ministration of modafinil and a selective serotonin reup-take inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebocontrolled study. J Clin Psychopharmacol 2007 Dec; 27 (6): 614-9
22. Fava M, Thase ME, DeBattista C. A multicenter, placebocontrolled study of modafinil augmentation in partial re-sponders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry 2005 Jan; 66 (1): 85-93
23. Fava M, Thase ME, DeBattista C, et al. Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness. Ann Clin Psychiatry 2007 Jul-Sep; 19 (3): 153-9
24. Lavretsky H, Park S, Siddarth P, et al. Methylphenidate-enhanced antidepressant response to citalopram in the elderly: a double-blind, placebocontrolled pilot trial. Am J Geriatr Psychiatry 2006 Feb; 14 (2): 181-5
25. Papakostas GI, Shelton RC, Smith J, et al. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry 2007 Jun; 68 (6): 826-31
26. Bauer M, Pretorius HW, Constant EL, et al. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebocontrolled, double-blind study. J Clin Psychiatry 2009 Apr; 70 (4): 540-9
27. Cutler AJ, Montgomery SA, Feifel D, et al. Extended re-lease quetiapine fumarate monotherapy in major depressive disorder: a placebo-and duloxetine-controlled study. J Clin Psychiatry 2009 Apr; 70 (4): 526-39
28. Chaput Y, Magnan A, Gendron A. The co-administration of quetiapine or placebo to cognitive-behavior therapy in treatment refractory depression: a preliminary trial. BMC Psychiatry 2008; 8: 73
29. Anderson IM, Sarsfield A, Haddad PM. Efficacy, safety and tolerability of quetiapine augmentation in treatment resistant depression: an open-label, pilot study. J Affect Disord 2009 Sep; 117 (1-2): 116-9
30. Garakani A, Martinez JM, Marcus S, et al. A randomized, double-blind, and placebocontrolled trialof quetiapine augmentation of fluoxetine in major depressive disorder. Int Clin Psychopharmacol 2008 Sep; 23 (5): 269-75
31. Pae CU, Sohi MS, Seo HJ, et al. Quetiapine XR: current status for the treatment of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2010 Oct 1; 34 (7): 1165-73
32. Croxtall JD, Scott LJ. Olanzapine/fluoxetine: a review of its use in patients with treatment-resistant major depressive disorder. CNS Drugs Mar 1; 24 (3): 245-62
33. Swainston Harrison T, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 2004; 64 (15): 1715-36
34. Molden E, Lunde H, Lunder N, et al. Pharmacokinet-ic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients. Ther Drug Monit 2006 Dec; 28 (6): 744-9
35. Kim JR, Seo HB, Cho JY, et al. Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients. Br J Clin Pharmacol 2008 Dec; 66 (6): 802-10
36. Kubo M, Koue T, Maune H, et al. Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism. Drug Metab Pharmacokinet 2007 Oct; 22 (5): 358-66
37. Zocchi A, Fabbri D, Heidbreder CA. Aripiprazole in-creases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex. Neurosci Lett 2005 Oct 28; 387 (3): 157-61
38. DeLeon A, Patel NC, Crismon ML. Aripiprazole: a com-prehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 2004 May; 26 (5): 649-66
39. Pae CU, Serretti A, Patkar AA, et al. Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence. CNS Drugs 2008; 22 (5): 367-88
40. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002 Jul; 302 (1): 381-9
41. Dhir A, Kulkarni SK. Involvement of dopamine (DA)/serotonin (5-HT)/sigma (sigma) receptor modulation in mediating the antidepressant action of ropinirole hydrochloride, a D2/D3 dopamine receptor agonist. Brain Res Bull 2007 Sep 14; 74 (1-3): 58-65
42. Renard CE, Fiocco AJ, Clenet F, et al. Is dopamine im-plicated in the antidepressant-like effects of selective sero-tonin reuptake inhibitors in the mouse forced swimming test? Psychopharmacology 2001 Dec; 159 (1): 42-50
43. Abilify® (aripiprazole): US prescribing information. Rockville (MD): Otsuka Pharmaceuticals Co. Inc., 2009
44. Bowles TM, Levin GM. Aripiprazole: a new atypical anti-psychotic drug. Ann Pharmacother 2003 May; 37 (5): 687-94
45. Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977 Oct; 229 (2): 327-36
46. Steru L, Chermat R, Thierry B, et al. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 1985; 85 (3): 367-70
47. Regenthal R, Koch H, Kohler C, et al. Depression-like deficits in rats improved by subchronic modafinil. Psychopharmacology 2009 Jul; 204 (4): 627-39
48. Carlezon Jr WA, Mague SD, Andersen SL. Enduring behavioral effects of early exposure to methylphenidate in rats. Biol Psychiatry 2003 Dec 15; 54 (12): 1330-7
49. Shimazu S, Minami A, Kusumoto H, et al. Antidepressant-like effects of selegiline in the forced swim test. Eur Neuropsychopharmacol 2005 Oct; 15 (5): 563-71
50. Bourin M, Chenu F, Prica C, et al. Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology 2009 Sep; 206 (1): 97-107
51. Kamei J, Miyata S, Sunohara T, et al. Potentiation of the antidepressant-like effect of fluoxetine by aripiprazole in the mouse tail suspension test. J Pharmacol Sci 2008 Nov; 108 (3): 381-4
52. Bortolozzi A, Diaz-Mataix L, Toth M, et al. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Psychopharmacology 2007 Apr; 191 (3): 745-58
53. Papp M, Klimek V, Willner P. Parallel changes in dopa-mine D2 receptor binding in limbic forebrain associated with chronic mild stress-induced anhedonia and its reversal by imipramine. Psychopharmacology 1994 Aug; 115 (4): 441-6
54. Moresco RM, Colombo C, Fazio F, et al. Effects of flu-voxamine treatment on the in vivo binding of [F-18]FESP in drug naive depressed patients: a PET study. Neuroimage 2000 Oct; 12 (4): 452-65
55. Bowden C, Theodorou AE, Cheetham SC, et al. Dopamine D1 and D2 receptor binding sites in brain samples from depressed suicides and controls. Brain Res 1997 Mar 28; 752 (1-2): 227-33
56. Willner P, Hale AS, Argyropoulos S. Dopaminergic mechanism of antidepressant action in depressed patients. J Affect Disord 2005; 86 (1): 37-45
57. Tadori Y, Kitagawa H, Forbes RA, et al. Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912. Eur J Pharmacol 2007 Nov 28; 574 (2-3): 103-11
58. Adson DE, Kushner MG, Fahnhorst TA. Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors. J Affect Disord 2005 May; 86 (1): 99-104
59. Papakostas GI, Petersen TJ, Kinrys G, et al. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry 2005 Oct; 66 (10): 1326-30
60. Pae CU, Patkar AA, Jun TY, et al. Aripiprazole augmentation for treatment of patients with inadequate antide-pressants response. Depress Anxiety 2007; 24 (7): 522-6
61. Simon JS, Nemeroff CB. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. J Clin Psychiatry 2005 Oct; 66 (10): 1216-20
62. Patkar AA, Peindl K, Mago R, et al. An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depression. Prim Care Companion J Clin Psychiatry 2006; 8 (2): 82-7
63. Rutherford B, Sneed J, Miyazaki M, et al. An open trialof aripiprazole augmentation for SSRI non-remitters with late-life depression. Int J Geriatr Psychiatry 2007 Oct; 22 (10): 986-91
64. Barbee JG, Conrad EJ, Jamhour NJ. Aripiprazole aug-mentation in treatment-resistant depression. Ann Clin Psychiatry 2004 Oct-Dec; 16 (4): 189-94
65. Worthington 3rd JJ, Kinrys G, Wygant LE, et al. Ari-piprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol 2005 Jan; 20 (1): 9-11
66. Schule C, Baghai TC, Eser D, et al. Mirtazapine mono-therapy versus combination therapy with mirtazapine and aripiprazole in depressed patients without psychotic features: a 4-week open-label parallel-group study. World J Biol Psychiatry 2007; 8 (2): 112-22
67. Hellerstein DJ, Batchelder S, Hyler S, et al. Aripiprazole as an adjunctive treatment for refractory unipolar depression. Prog Neuropsychopharmacol Biol Psychiatry 2008 Apr 1; 32 (3): 744-50
68. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebocontrolled study. J Clin Psychiatry 2007 Jun; 68 (6): 843-53
69. Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebocontrolled study. J Clin Psychopharmacol 2008 Apr; 28 (2): 156-65
70. Berman RM, Fava M, Thase ME, et al. Aripiprazole aug-mentation in major depressive disorder: a double-blind, placebocontrolled study in patients with inadequate response to antidepressants. CNS Spectr 2009 Apr; 14 (4): 197-206
71. Thase ME, Trivedi MH, Nelson JC, et al. Examining the efficacy of adjunctive aripiprazole in major depressive disorder: a pooled analysis of 2 studies. Prim Care Companion J Clin Psychiatry 2008; 10 (6): 440-7
72. Vis PM, van Baardewijk M, Einarson TR. Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials. Ann Pharmacother 2005 Nov; 39 (11): 1798-807
73. Rudolph RL, Feiger AD. A double-blind, randomized, placebocontrolled trialof once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord 1999 Dec; 56 (2-3): 171-81
74. Thase ME, Kornstein SG, Germain JM, et al. An inte-grated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. CNS Spectr 2009 Mar; 14 (3): 144-54
75. Hansen R, Gaynes B, Thieda P, et al. Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants. Psychiatr Serv 2008 Oct; 59 (10): 1121-30 Data on file, Otsuka Pharmaceuticals, Inc., 2009
76. Berman RM, Hazel J, Swanink R, et al. Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder (study CN138-164). American Psychiatric Association 161st Annual Meeting; 2008 May 3-8; Washington, DC
77. Pae CU. A review of the safety and tolerability of ari-piprazole. Expert Opin Drug Saf 2009 May; 8 (3): 373-86
78. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002 Sep; 63 (9): 763-71
79. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebocontrolled trials. Schizophr Res 2003 Jun 1; 61 (2-3): 123-36
80. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and ris-peridone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003 Jul; 60 (7): 681-90
81. Gao K, Kemp DE, Ganocy SJ, et al. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol 2008 Apr; 28 (2): 203-9
82. Lane RM. SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment. J Psychopharmacol 1998; 12 (2): 192-214
83. Pigott TA, Carson WH, Saha AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebocontrolled 26-week study. J Clin Psychiatry 2003 Sep; 64 (9): 1048-56
84. Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 2007 Jan; 100 (1): 4-22
85. Urichuk L, Prior TI, Dursun S, et al. Metabolism of atyp-ical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab 2008 Jun; 9 (5): 410-8
86. Conley RR, Kelly DL. Drug-drug interactions associated with second-generation antipsychotics: considerations for clinicians and patients. Psychopharmacol Bull 2007; 40 (1): 77-97
87. Boulton D, Balch A, Royzman K, et al. The pharmaco-kinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder. J Psychopharmacol 2010 Apr; 24 (4): 537-46
88. Bauman JN, Frederick KS, Sawant A, et al. Comparison of the bioactivation potentialof the antidepressant and hepatotoxin nefazodone with aripiprazole, a structural analog and marketed drug. Drug Metab Dispos 2008 Jun; 36 (6): 1016-29
89. Raggi MA, Mandrioli R, Sabbioni C, et al. Atypical anti-psychotics: pharmacokinetics, therapeutic drug monitor-ing and pharmacological interactions. Curr Med Chem 2004 Feb; 11 (3): 279-96
90. Schieber FC, Boulton DW, Balch AH, et al. A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmaco-kinetics of lamotrigine in patients with bipolar I disorder. Hum Psychopharmacol 2009 Mar; 24 (2): 145-52
91. Nierenberg AA, McLean NE, Alpert JE, et al. Early non-response to fluoxetine as a predictor of poor 8-week outcome. Am J Psychiatry 1995 Oct; 152 (10): 1500-3
92. Nierenberg AA, Farabaugh AH, Alpert JE, et al. Timing of onset of antidepressant response with fluoxetine treatment. Am J Psychiatry 2000 Sep; 157 (9): 1423-8
93. Papakostas GI, Petersen T, Sklarsky KG, et al. Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. Psychiatry Res 2007 Jan 15; 149 (1-3): 195-200
94. Henkel V, Seemuller F, Obermeier M, et al. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression. J Affect Disord 2009 Jun; 115 (3): 439-49
95. Huynh NN, McIntyre RS. What are the implications of the STAR*D trial for primary care? A review and synthesis. Prim Care Companion J Clin Psychiatry 2008; 10 (2): 91-6
96. Papakostas GI, Montgomery SA, Thase ME, et al. Com-paring the rapidity of response during treatment of major depressive disorder with bupropion and the SSRIs: a pooled survival analysis of 7 double-blind, randomized clinical trials. J Clin Psychiatry 2007 Dec; 68 (12): 1907-12
97. Stewart JW. Treating depression with atypical features. J Clin Psychiatry 2007; 68 Suppl. 3: 25-9
98. Liebowitz MR, Quitkin FM, Stewart JW, et al. Antide-pressant specificity in atypical depression. Arch Gen Psychiatry 1988 Feb; 45 (2): 129-37
99. Stewart JW, McGrath PJ, Fava M, et al. Do atypical features affect outcome in depressed outpatients treated with citalopram? Int J Neuropsychopharmacol 2010 Feb; 13 (1): 15-30
100. Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry 2008 Mar; 165 (3): 342-51
101. Trivedi MH, Thase ME, Fava M, et al. Adjunctive ari-piprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features. J Clin Psychiatry 2008 Dec; 69 (12): 1928-36
102. Fredman SJ, Fava M, Kienke AS, et al. Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current "nextstep" practices. J Clin Psychiatry 2000 Jun; 61 (6): 403-8
103. Marks DM, Pae CU, Patkar AA. Triple reuptake in-hibitors: a premise and promise. Psychiatry Investig 2008 Sep; 5 (3): 142-7